Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.48 |
| ▸ | JAK1 | P23458 | 2/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.40 |
| ▸ | ZAP70 | P43403 | 5/20 | 0.39 |
| ▸ | GLP1R | P43220 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15760946 | 0.84 | CHEK1 (0.43) | JAK2CHEK1ZAP70ROCK2 | |
| SCHEMBL15540146 | 0.81 | CHEK1 (0.43) | JAK2CHEK1ZAP70ROCK2 | |
| SCHEMBL1159618 | 0.80 | JAK2 (0.49) | JAK2CHEK1ZAP70ROCK2 | |
| SCHEMBL12794862 | 0.77 | ESR1 (0.38) | JAK2CHEK1ZAP70ROCK2 | |
| SCHEMBL12848802 | 0.75 | CHEK1 (0.46) | JAK2CHEK1ROCK2 | |
| SCHEMBL1159415 | 0.75 | CHEK1 (0.38) | JAK2CHEK1ZAP70ROCK2 | |
| SCHEMBL1050400 | 0.75 | CHEK1 (0.49) | JAK2CHEK1ROCK2 | |
| SCHEMBL30381452 | 0.75 | CHEK1 (0.49) | JAK2CHEK1ROCK2 | |
| SCHEMBL1159263 | 0.75 | SYK (0.50) | JAK2JAK1ZAP70PIM1PIM3 | |
| SCHEMBL1159381 | 0.73 | JAK2 (0.41) | JAK2JAK1CHEK1ZAP70 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459556-A1 | 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2012-06-06 | — | — | EP | disclosed |
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| WO-2011014515-A1 | 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011014515-A1 | 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | SYK, BTK, LYN | JAK2 19/4885JAK1 42/4885CHEK1 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.